Difference between revisions of "Timeline of hemophilia"

From Timelines
Jump to: navigation, search
Line 74: Line 74:
 
|-
 
|-
 
| 1960 || || The life expectancy of a person with severe hemophilia rises to just under 20 years old.<ref name="A Brief History of Hemophilia Treatment"/> ||
 
| 1960 || || The life expectancy of a person with severe hemophilia rises to just under 20 years old.<ref name="A Brief History of Hemophilia Treatment"/> ||
 +
|-
 +
| 1961 || || "First use of FVIII concentrates"<ref name="Production of Plasma Proteins for Therapeutic Use"/> ||
 
|-
 
|-
 
| 1964 || || An article published in ''[[w:Nature (journal)|Nature]]'' describes the clotting process in detail. The interaction of the different factors in blood clotting is named coagulation cascade.<ref name="History of hemophiliav"/> ||
 
| 1964 || || An article published in ''[[w:Nature (journal)|Nature]]'' describes the clotting process in detail. The interaction of the different factors in blood clotting is named coagulation cascade.<ref name="History of hemophiliav"/> ||
Line 96: Line 98:
 
|-
 
|-
 
| 1985 || || The first inactivated factor concentrates become available.<ref name="HISTORY OF BLEEDING DISORDERS"/> ||
 
| 1985 || || The first inactivated factor concentrates become available.<ref name="HISTORY OF BLEEDING DISORDERS"/> ||
 +
|-
 +
| 1985 || || "First SD-treated FVIII concentrates"<ref name="Production of Plasma Proteins for Therapeutic Use"/> ||
 +
|-
 +
| 1988 || || "First high purity FVIII concentrates"<ref name="Production of Plasma Proteins for Therapeutic Use"/> ||
 
|-
 
|-
 
| 1980s || || Factor VIII, FIX and von Willebrand factor genes are cloned.<ref name="HISTORY OF BLEEDING DISORDERS"/> ||
 
| 1980s || || Factor VIII, FIX and von Willebrand factor genes are cloned.<ref name="HISTORY OF BLEEDING DISORDERS"/> ||
Line 101: Line 107:
 
| 1992 || || Blood screening is introduced. Prior to this, hemophiliacs were at a high risk of contracting {{w|hepatitis C}} and other diseases.<ref name="A Brief History of Hemophilia Treatment"/> ||
 
| 1992 || || Blood screening is introduced. Prior to this, hemophiliacs were at a high risk of contracting {{w|hepatitis C}} and other diseases.<ref name="A Brief History of Hemophilia Treatment"/> ||
 
|-
 
|-
| 1992 || || The first recombinant factor VIII product is approved by the United States {{w|Food and Drug Administration}}.<ref name="HISTORY OF BLEEDING DISORDERS"/><ref name="A Brief History of Hemophilia Treatment"/> || {{w|United States}}
+
| 1992 || || The first recombinant factor VIII product is approved by the United States {{w|Food and Drug Administration}}.<ref name="HISTORY OF BLEEDING DISORDERS"/><ref name="A Brief History of Hemophilia Treatment"/><ref name="Production of Plasma Proteins for Therapeutic Use"/> || {{w|United States}}
 
|-
 
|-
 
| 1995 || || Prophylaxis starts being used as a preventive treatment for children.<ref name="HISTORY OF BLEEDING DISORDERS"/><ref name="A Brief History of Hemophilia Treatment"/> ||
 
| 1995 || || Prophylaxis starts being used as a preventive treatment for children.<ref name="HISTORY OF BLEEDING DISORDERS"/><ref name="A Brief History of Hemophilia Treatment"/> ||

Revision as of 18:41, 22 October 2018

This is a timeline of hemophilia.

Big picture

Time period Development summary.
Ancient times Hemophilia is recognized, though not named.[1]
19th century While the history of hemophilia dates back to the 2nd century AD, a modern description of hemophilia appears only at the beginning of the 19th century.[2] Hemophilia figures prominently in the history of European royalty in the 19th and following century. Britain's Queen Victoria, through two of her five daughters (Princess Alice and Princess Beatrice), passes the mutation to various royal houses across the continent, including the royal families of Spain, Germany and Russia.[3]
20th century Until the early 1900s, there is no way to store blood for hemophiliacs so they are generally given a transfusion from a family member if they have suffered a trauma. At this point, the life expectancy for boys with hemophilia is around 13 years old. Some of the early treatments include lime, bone marrow, oxygen, thyroid gland, hydrogen peroxide or gelatin. In the 1930s, snake venom is used to help blood clotting. Hospital-based plasma transfusions are common treatments for hemophiliacs in the late 1920s and continue until the 1950s. The different factor deficiencies are distinguished in the 1950s and 1960s. By 1960, the life expectancy of a person with severe hemophilia rises to just under 20 years old. By the 1970s, freeze-dried powder formulas of factor VIII and IX become readily available, which means hemophiliacs are able to self-administer the factor in their own homes. In the 1980s, the rise of HIV and AIDS leads to many people with hemophilia dying of AIDS and becoming HIV positive through contaminated blood products. Hemophiliacs are also at a high risk of contracting hepatitis C until blood screening is introduced in 1992.[4] In the 1990s, modern treatment, using safer factor concentrates, again improves the outlook of hemophilia.[1]
21st century New recombinant factors not containing contain human or animal plasma are introduced in the early 2000s, lessening the chance of allergic reactions. Currently, researchers are working on ways of correcting the mutated gene using viruses as vehicles to deliver corrected factor IX genes.[4]

Full timeline

Year Event type Details Location
2nd century AD Field development The first written reference to a bleeding disorder appears in the Babylonian Talmud.[5][1]
12th century Arab physician Albucasis authors the first written reference to hemophilia treatment.[1][5]
1803 Dr. John Conrad Otto from Philadelphia publishes a paper about a familial bleeding disorder that only affected male members.[4][1] United States
1828 Field development Friedrich Hopff at the University of Zurich writes the word hemophilia in a description of the condition.[4][1][6] Switzerland
1840 The first successful blood transfusion in a hemophilic boy is conducted.[5]
1901 The United States Surgeon General’s Catalogue lists lime, inhaled oxygen and the use of thyroid gland or bone marrow, or hydrogen peroxide or gelatin, as treatments for hemophilia.[7] United States
1920 Factor I deficiency is first described.[7]
1925–1930 Hospital-based plasma transfusions become common treatments for hemophiliacs.[4]
1926 "In 1926 Finnish physician Erik von Willebrand published a paper describing what he called “pseudohemophilia,” a bleeding disorder affecting men and women equally. It was later named von Willebrand disease. "[7]
1930 Scientists learn how to separate blood into its major parts, plasma and red cells.[8]
1934 Snake venom is used to help blood clotting.[4][5]
1936 The first plasma treatment for hemophilia is conducted.[5]
1937 " Then, in 1937, Patek and Taylor, two doctors at Harvard, found they could correct the clotting problem by adding a substance which came from the plasma in blood. This was called anti-hemophilic globulin."[1]
1930s Doctors look at defective platelets as the likely cause of hemophilia.[1]
1944 "In 1944, Pavlosky, a doctor from Buenos Aires, Argentina, did a lab test which showed that blood from one hemophiliac could correct the clotting problem in a second hemophiliac and vice-versa." Argentina
1946 "Cohn Fraction I"[5]
1947 "Argentinian physician, Alfredo Pavlovsky discovered there were two types of hemophilia (A and B) in 1947."[4] Argentina
1948 The National Hemophilia Foundation (NHF) opens as The Hemophilia Foundation, Inc.[7]
1940s Factors II and V deficiency are identified.[7]
1940s Whole blood transfusions start being given at hospitals.[7]
1952 "This led to the recognition in 1952 of hemophilia A and hemophilia B as two distinct diseases."[1]
1952 Factor IX is identified in a patient with hemophilia B.[7][6]
1955 The first infusions of factor VIII in plasma form are performed.[7]
1957 "Researchers in Sweden identify von Willebrand factor as the cause of VWD"[7] Sweden
1958 Prophylaxis for hemophilia A is first used.[7]
1955–1965 Hemophiliacs are treated with whole blood or fresh plasma.[1]
1960 The life expectancy of a person with severe hemophilia rises to just under 20 years old.[4]
1961 "First use of FVIII concentrates"[5]
1964 An article published in Nature describes the clotting process in detail. The interaction of the different factors in blood clotting is named coagulation cascade.[1]
1965 Dr. Judith Graham Pool from Stanford University discovers a process of freezing and thawing plasma to get a layer of factor-rich plasma (cryoprecipitate).[8] Graham Pool discovers that the cryoprecipitate left from thawing plasma is high in factor VIII. This could be infused to control heavy bleeding allowing blood banks to produce and store large amounts for use in surgical procedures for hemophiliacs.[4] United States
1968 The first FVIII concentrate becomes available.[7]
1965–1975 Concentrates containing factor VIII and IX begin to be available.[1]
1960s The clotting factors are identified and named.[1]
1977 Desmopressin is identified to treat mild hemophilia and von Willebrand disease.[7]
1970s Primary prophylaxis therapy experiments begin.[7]
1970s Freeze-dried plasma-derived factor concentrates become available.[7]
1982 The United States Centers for Disease Control and Prevention reports first AIDS cases among people with hemophilia.[7]
1984 "First heat-treated FVIII concentrates"[5]
1985 The first inactivated factor concentrates become available.[7]
1985 "First SD-treated FVIII concentrates"[5]
1988 "First high purity FVIII concentrates"[5]
1980s Factor VIII, FIX and von Willebrand factor genes are cloned.[7]
1992 Blood screening is introduced. Prior to this, hemophiliacs were at a high risk of contracting hepatitis C and other diseases.[4]
1992 The first recombinant factor VIII product is approved by the United States Food and Drug Administration.[7][4][5] United States
1995 Prophylaxis starts being used as a preventive treatment for children.[7][4]
1997 The first recombinant factor IX product is approved by the United States Food and Drug Administration.[7] United States
1997 A bypassing agent is developed, offering patients an alternative product to help stop bleeds and joint damage.[7]
1998 First human gene therapy trials begin.[7]
2009 The United States Food and Drug Administration approves RiaSTAP to treat factor I deficiency.[7] United States
2011 The United States Food and Drug Administration approves Corifact to treat factor XIII deficiency.[7] United States

Meta information on the timeline

How the timeline was built

The initial version of the timeline was written by FIXME.

Funding information for this timeline is available.

Feedback and comments

Feedback for the timeline can be provided at the following places:

  • FIXME

What the timeline is still missing

Timeline update strategy

See also

External links

References

  1. 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 "History of hemophilia". hemophilia.ca. Retrieved 22 October 2018. 
  2. Franchini, M; Mannucci, PM. "The history of hemophilia.". PMID 24911674. doi:10.1055/s-0034-1381232. 
  3. "Hemophilia: "The Royal Disease"". hemophiliaprince.com. Retrieved 22 October 2018. 
  4. 4.00 4.01 4.02 4.03 4.04 4.05 4.06 4.07 4.08 4.09 4.10 4.11 "A Brief History of Hemophilia Treatment". hemophilianewstoday.com. Retrieved 22 October 2018. 
  5. 5.00 5.01 5.02 5.03 5.04 5.05 5.06 5.07 5.08 5.09 5.10 Goss, Neil. Production of Plasma Proteins for Therapeutic Use. 
  6. 6.0 6.1 Rippe, James M. Encyclopedia of Lifestyle Medicine and Health. 
  7. 7.00 7.01 7.02 7.03 7.04 7.05 7.06 7.07 7.08 7.09 7.10 7.11 7.12 7.13 7.14 7.15 7.16 7.17 7.18 7.19 7.20 7.21 7.22 7.23 "HISTORY OF BLEEDING DISORDERS". hawaiinhf.org. Retrieved 22 October 2018. 
  8. 8.0 8.1 "The History of Hemophilia". hog.org. Retrieved 22 October 2018.